Skip to content
Bomb Report – Lifestyle
Author:
InflaRx N.V.
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
November 6, 2026
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
November 3, 2026
InflaRx Announces November Investor Events
October 27, 2026
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
October 22, 2026
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
October 2, 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
October 1, 2026
InflaRx to Host Virtual Capital Markets Day
September 21, 2026
InflaRx Announces Participation in September Investor Conferences
August 20, 2026
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
August 6, 2026
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
July 30, 2026
1
2
Next Page
→